The effects of RPL554 in addition to tiotropium in COPD patients

Phase 1

• Conditions: MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]; Chronic obstructive pulmonary disease (COPD)

• Registration Number: EUCTR2016-004450-15-GB
• Lead Sponsor: Verona Pharma plc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-29
• Study Completion: 2017-07-24
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
2. Male or female aged between 40 and 75 years inclusive, at the time of informed consent.
3. If male: must agree to meet the following from the first dose up to 2 months after the last dose of study treatment:
• Not donate sperm
• Either: be sexually abstinent in accordance with a patient’s usual and preferred lifestyle (but agree to abide by the contraception requirements below should their circumstances change)
Or: use a condom with all sexual partners. If the partner is of childbearing potential the condom must be used with spermicide and a second highly effective form of contraception must also be used (as defined in Section 8.4)
4. If female: either be:
a) Of non-childbearing potential defined as being:
• Either: post-menopausal (being spontaneously amenorrhoeic for at least 1 year with an appropriate clinical profile [e.g. age appropriate, history of vasomotor symptoms]
• Or: permanently sterilised e.g. tubal occlusion, hysterectomy, bilateral oophorectomy, bilateral salpingectomy
b) Of childbearing potential and agreeing to use a highly effective method of contraception (as defined in protocol section 8.4) until completion of the end of study visit.
5. Have a 12-lead ECG recording at screening and randomisation (pre-dose in Treatment Period 1) showing the following:
• Heart rate between 45 and 90 beats per minute (bpm)
• QT interval corrected for heart rate using Fridericia’s formula (QTcF) =450 msec for males and =470 ms for females
• QRS interval =120 msec
• No clinically significant abnormalities (as judged by the Investigator) including morphology (e.g. left bundle branch block, atrio-ventricular nodal dysfunction, ST segment abnormalities)
6. Have a screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of patient safety or which may significantly impairs interpretation in the opinion of the Investigator including:
• Significant arrhythmias including atrial flutter, atrial fibrillation, ventricular tachycardia
• Any symptomatic arrhythmia (except isolated extra systoles)
• Any sustained second or third degree heart block
7. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser and HandiHaler® DPI correctly.
8. Body mass index (BMI) between 18 and 33 kg/m2 (inclusive) with a minimum weight of 45 kg.
9. COPD diagnosis: Patients with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli and MacNee, 2004) with symptoms compatible with COPD for at least 1 year prior to screening.
10. Post-bronchodilator (four puffs of salbutamol) spirometry at screening:
• Post-bronchodilator FEV1/FVC ratio of =0.70
• Post-bronchodilator FEV1 =40 % and =80% of predicted normal
• Demonstrates =150 mL increase from pre-br

Exclusion Criteria

1. A history of life-threatening COPD exacerbation including Intensive Care Unit admission and/or requiring intubation.
2. COPD exacerbation requiring oral steroids, or lower respiratory tract infection requiring antibiotics, in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).
3. A history of one or more hospitalisations for COPD in the 12 months prior to screening or randomisation (pre-dose in Treatment Period 1).
4. Lactation (female patients only).
5. Positive urine or serum pregnancy test at screening, or a positive urine pregnancy test prior to randomisation (female patients of childbearing potential only).
6. Known hypersensitivity to RPL554 or its components.
7. Intolerance or hypersensitivity to tiotropium.
8. Evidence of cor pulmonale.
9. Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
10. Previous lung resection or lung reduction surgery.
11. Use of oral COPD medications (e.g. oral steroids, theophylline and romifulast) in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).
12. History of, or reason to believe, a patient has drug or alcohol abuse within the past 3 years.
13. Inability to perform technically acceptable spirometry or whole body plethysmography (at screening or randomisation [pre-dose in Treatment Period 1])
14. Received an experimental drug within 30 days or five half-lives, whichever is longer.
15. Patients with a history of chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological, or ophthalmic diseases that the Investigator believes are clinically significant.
16. Documented cardiovascular disease: arrhythmias, angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in the 3 months prior to screening or randomisation.
17. Concurrent use of non-cardioselective oral beta-blockers.
18. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening or randomisation (pre-dose in Treatment Period 1), or will not have fully recovered from surgery, or planned surgery through the end of the study.
19. A disclosed history or one known to the Investigator, of significant non-compliance in previous investigational studies or with prescribed medications.
20. Requires oxygen therapy, even on an occasional basis.
21. Clinically significant prostatic hyperplasia (judged by the Investigator) or bladder-neck obstruction or with narrow-angle glaucoma.
22. Any other reason that the Investigator considers makes the patient unsuitable to participate.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified